Personalized Cancer Vaccine Reduces Melanoma Recurrence by 49%
Phase IIb results show that adding a personalized mRNA vaccine to standard immunotherapy after surgery can reduce the five-year risk of recurrence and death by...
Phase IIb results show that adding a personalized mRNA vaccine to standard immunotherapy after surgery can reduce the five-year risk of recurrence and death by 49% among patients with advanced melanoma. The post Personalized Cancer Vaccine Reduces Melanoma Recurrence by 49% appeared first on Inside Precision Medicine .